Latest Breaking News On - Agenzia italiana del farmaco - Page 5 : comparemela.com

Alterity Therapeutics : Appendix 4C – Q4 FY22 Quarterly Cash Flow Report - Form 6-K

Alterity Therapeutics : Appendix 4C – Q4 FY22 Quarterly Cash Flow Report - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited statesUnited kingdomSan franciscoRemy bernardaPhillip hainsDavid stamlerRebecca wilsonNational institute of healthTrademark officeAustralian taxation officeAlterity therapeutics limitedItalian medicines agencyAlterity therapeuticsZealand brain research instituteLife sciences investor forum

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report

Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.

New zealandUnited statesUnited kingdomSan franciscoDavid stamlerLife sciences investor forumNational institute of healthEuropean commissionCompany healthcare house call conferenceRegulatory agencyTrademark officeAustralian taxation officeGlobal chinese financial forumAmerican academy of neurologyItalian medicines agencyAlterity therapeutics limited

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

/PRNewswire/ Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying.

United kingdomUnited statesNew zealandSan franciscoDavid stamlerNational institute of healthEuropean commissionAlterity therapeuticsItalian medicines agencyAgenzia italiana del farmacoMultiple system atrophyChief executive officerSystem atrophyNeurological disordersMultiple system atrophy factSecurities act

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesNew zealandSan franciscoDavid stamlerNational institute of healthEuropean commissionAlterity therapeuticsItalian medicines agencyAgenzia italiana del farmacoMultiple system atrophyChief executive officerSystem atrophyNeurological disordersMultiple system atrophy fact

Orchard Therapeutics Announces Reimbursement Agreement Making Libmeldy Available for All Eligible MLD Patients in Italy

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomUnited statesCity ofBraden parkerEuropean commissionTelethon institute for gene therapyExchange commissionEuropean unionSan raffaele telethon institute for gene therapyItalian medicines agencyAgenzia italiana del farmacoMiddle eastOspedale san raffaeleProduct characteristicsSan raffaele telethon instituteGene therapy